Natixis Purchases New Shares in Core Laboratories Inc. (NYSE:CLB)

Natixis bought a new position in shares of Core Laboratories Inc. (NYSE:CLB - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 30,050 shares of the oil and gas company's stock, valued at approximately $520,000. Natixis owned about 0.06% of Core Laboratories as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the stock. Franklin Resources Inc. bought a new stake in shares of Core Laboratories during the fourth quarter worth about $464,000. Geode Capital Management LLC grew its holdings in Core Laboratories by 0.7% during the third quarter. Geode Capital Management LLC now owns 1,053,204 shares of the oil and gas company's stock valued at $19,521,000 after purchasing an additional 7,721 shares during the period. Boston Trust Walden Corp lifted its position in shares of Core Laboratories by 2.7% during the 4th quarter. Boston Trust Walden Corp now owns 617,336 shares of the oil and gas company's stock valued at $10,686,000 after buying an additional 16,503 shares during the last quarter. Amundi increased its holdings in Core Laboratories by 194.8% in the 4th quarter. Amundi now owns 32,968 shares of the oil and gas company's stock worth $600,000 after acquiring an additional 21,783 shares during the last quarter. Finally, Barclays PLC lifted its stake in shares of Core Laboratories by 288.2% during the 3rd quarter. Barclays PLC now owns 83,570 shares of the oil and gas company's stock valued at $1,549,000 after buying an additional 62,042 shares in the last quarter. 97.81% of the stock is currently owned by institutional investors.

Core Laboratories Trading Down 4.6 %

CLB stock traded down $0.55 on Monday, reaching $11.31. The company's stock had a trading volume of 478,231 shares, compared to its average volume of 392,352. Core Laboratories Inc. has a 12-month low of $10.14 and a 12-month high of $25.13. The firm has a market cap of $528.20 million, a PE ratio of 17.14, a PEG ratio of 0.99 and a beta of 1.99. The business has a fifty day simple moving average of $13.98 and a two-hundred day simple moving average of $17.16. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.71 and a current ratio of 2.32.

Core Laboratories (NYSE:CLB - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The oil and gas company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.01). The company had revenue of $123.59 million for the quarter, compared to the consensus estimate of $125.09 million. Core Laboratories had a net margin of 5.99% and a return on equity of 16.24%. Core Laboratories's revenue was down 4.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.19 earnings per share. As a group, research analysts forecast that Core Laboratories Inc. will post 0.96 EPS for the current year.

Core Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, May 27th. Stockholders of record on Monday, May 5th will be paid a $0.01 dividend. The ex-dividend date of this dividend is Monday, May 5th. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.35%. Core Laboratories's dividend payout ratio (DPR) is currently 6.78%.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on CLB. StockNews.com cut Core Laboratories from a "hold" rating to a "sell" rating in a research report on Friday. Stifel Nicolaus lowered their price target on Core Laboratories from $19.00 to $15.00 and set a "hold" rating on the stock in a research report on Tuesday, April 15th. Finally, Citigroup raised shares of Core Laboratories from a "sell" rating to a "neutral" rating and boosted their price target for the stock from $15.00 to $16.00 in a research note on Wednesday, March 12th. Two analysts have rated the stock with a sell rating and three have given a hold rating to the company's stock. Based on data from MarketBeat.com, Core Laboratories currently has a consensus rating of "Hold" and an average target price of $15.75.

Core Laboratories Company Profile

Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.